Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Agnes Paquet

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
AIDS Research and Human Retroviruses|November 22, 2011
Short communication: Phenotypic protease inhibitor resistance and cross-resistance in the clinic from 2006 to 2008 and mutational prevalences in HIV from patients with discordant tipranavir and darunavir susceptibility phenotypesRichard Bethell, Joseph Scherer, Myriam Witvrouw, et al.
AIDS Research and Human Retroviruses|February 17, 2015
Trends in darunavir resistance-associated mutations and phenotypic resistance in commercially tested United States clinical samples between 2006 and 2012Erkki Lathouwers, Soumi Gupta, Mojgan Haddad, et al.
F1000Research|June 28, 2016
RiboProfiling: a Bioconductor package for standard Ribo-seq pipeline processingAlexandra Popa, Kevin Lebrigand, Agnes Paquet, et al.
Cancer|July 28, 2010
Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumabAllan Lipton, Wolfgang J Köstler, Kim Leitzel, et al.
Briefings in Bioinformatics|June 3, 2017
Optimizing drug development in oncology by clinical trial simulation: Why and how?Jocelyn Gal, Gérard Milano, Jean-Marc Ferrero, et al.
Toxicology in Vitro : an International Journal Published in Association with BIBRA|January 23, 2016
SENS-IS, a 3D reconstituted epidermis based model for quantifying chemical sensitization potency: Reproducibility and predictivity results from an inter-laboratory studyFrançoise Cottrez, Elodie Boitel, Jean-Claude Ourlin, et al.
American Journal of Clinical Pathology|July 28, 2010
Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximity-based assayWeidong Huang, Monica Reinholz, Jodi Weidler, et al.
Plos One|August 1, 2012
Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancerSae-Won Han, Yongjun Cha, Agnes Paquet, et al.
The Oncologist|January 12, 2012
Correlation between quantitative HER-2 protein expression and risk for brain metastases in HER-2+ advanced breast cancer patients receiving trastuzumab-containing therapyRenata Duchnowska, Wojciech Biernat, Barbara Szostakiewicz, et al.
Neuro-Oncology|February 15, 2015
Quantitative HER2 and p95HER2 levels in primary breast cancers and matched brain metastasesRenata Duchnowska, Jeff Sperinde, Ahmed Chenna, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
AIDS Research and Human Retroviruses|November 22, 2011
Short communication: Phenotypic protease inhibitor resistance and cross-resistance in the clinic from 2006 to 2008 and mutational prevalences in HIV from patients with discordant tipranavir and darunavir susceptibility phenotypesRichard Bethell, Joseph Scherer, Myriam Witvrouw, et al.
AIDS Research and Human Retroviruses|February 17, 2015
Trends in darunavir resistance-associated mutations and phenotypic resistance in commercially tested United States clinical samples between 2006 and 2012Erkki Lathouwers, Soumi Gupta, Mojgan Haddad, et al.
F1000Research|June 28, 2016
RiboProfiling: a Bioconductor package for standard Ribo-seq pipeline processingAlexandra Popa, Kevin Lebrigand, Agnes Paquet, et al.
Cancer|July 28, 2010
Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumabAllan Lipton, Wolfgang J Köstler, Kim Leitzel, et al.
Briefings in Bioinformatics|June 3, 2017
Optimizing drug development in oncology by clinical trial simulation: Why and how?Jocelyn Gal, Gérard Milano, Jean-Marc Ferrero, et al.
Toxicology in Vitro : an International Journal Published in Association with BIBRA|January 23, 2016
SENS-IS, a 3D reconstituted epidermis based model for quantifying chemical sensitization potency: Reproducibility and predictivity results from an inter-laboratory studyFrançoise Cottrez, Elodie Boitel, Jean-Claude Ourlin, et al.
American Journal of Clinical Pathology|July 28, 2010
Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximity-based assayWeidong Huang, Monica Reinholz, Jodi Weidler, et al.
Plos One|August 1, 2012
Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancerSae-Won Han, Yongjun Cha, Agnes Paquet, et al.
The Oncologist|January 12, 2012
Correlation between quantitative HER-2 protein expression and risk for brain metastases in HER-2+ advanced breast cancer patients receiving trastuzumab-containing therapyRenata Duchnowska, Wojciech Biernat, Barbara Szostakiewicz, et al.
Neuro-Oncology|February 15, 2015
Quantitative HER2 and p95HER2 levels in primary breast cancers and matched brain metastasesRenata Duchnowska, Jeff Sperinde, Ahmed Chenna, et al.
Pageof 2